BioMarin Pharmaceutical Inc (BMRN) has outlined a strategic plan to achieve $4 billion in revenue by 2027, with a focus on expanding existing products and launching new therapies. The company aims for a 40% operating margin by 2026, driven by cost optimization and growth in its key areas: skeletal conditions, enzyme therapies, and its hemophilia A gene therapy Roctavian.
BioMarin Pharmaceutical (BMRN) released updated 2024 guidance with its Q1 2024 financial results, boosting non-GAAP diluted EPS range while maintaining revenue expectations. Non-GAAP EPS guidance was raised to $2.75-$2.95 from $2.60-$2.80, with consensus at $2.75. Revenue is still projected at $2.7B-$2.8B, meeting consensus of $2.76B. Despite missing revenue estimates in Q1, the company beat on earnings, with Vimizim and Voxzogo driving growth.
